IDS Dated February 17, 2004 Attorney Docket No. 1256-00947 Applicants: Hector F. DeLuca et al

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Divisional o	f:	Hector F. DeLuca Rafal R. Sicinski)	CERTIFICATE OF EXPRESS MAIL This is to certify that this correspondence is
Title	:	26,27-Homologated- 20-EPI-2-Alkylidene- 19-Nor-Vitamin D Compounds))))	being deposited with the United States Postal Service as Express Mail Post Office to Addressee in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 17th
Docket No.	:	1256-00947)	day of February, 2004. The Express Mail
PARENT A	PPI	LICATION DATA:)	Label is EV383674403US.
Appln. No. Filed Title	: :	10/352,745 January 28, 2003 26,27-Homologated- 20-EPI-2-Alkylidene- 19-Nor-Vitamin D Compounds))))))	Dorothy A. Hauser Date
TC/A.U. Examiner	:	1616 Qazi, Sabiha Naim))	I OOLIDE GEATEN GENER
		INFORMATION DIS	SC	LOSURE STATEMENT

Mail Stop: Divisional Application

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

The references listed on the enclosed PTO Form 1449 are being submitted in the above-identified patent application in accordance with 37 CFR 1.97(b)(1).

A copy of each of the listed references is enclosed in compliance with the rules.

Respectfully submitted,

ANDRUS, SCEALES, STARKE & SAWALL, LLP

Bv

Thomas M. Wozny Reg. No. 28,922

(414) 271-7590

Andrus, Sceales, Starke & Sawall, LLP 100 East Wisconsin Avenue, Suite 1100 Milwaukee, Wisconsin 53202

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known			
				Application Number			
INI	FORMATIO	N DIS	CLOSUDE	Filing Date	February 17, 2004		
				First Named Inventor	Hector F. DeLuca		
S	TATEMENT			Art Unit	1616		
	(Use as many si	heets as n	ecessary)	Examiner Name	Qazi, Sabiha Naim		
Sheet	1	of	4	Attorney Docket Number	1256-00947		

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 6,392,071	05-21-2002	DeLuca et al	
		^{US-} 5,945,410	08-31-1999	DeLuca et al	
		^{US-} 5,936,133	08-10-1999	DeLuca et al	
		^{US-} 5,877,168	03-02-1999	Miyamoto et al	
		^{US-} 5,849,726	12-15-1988	Brenner	
		^{US-} 5,846,960	12-08-1998	Labrie	
		^{US-} 5,843,928	12-01-1998	DeLuca et al	
		^{US-} 5,843,927	12-01-1998	DeLuca	
		^{US-} 5,817,648	10-06-1998	Kutner et al	
		^{US-} 5,587,497	12-24-1996	DeLuca et al	
		^{US-} 5,536,713	07-16-1996	DeLuca et al	
		^{US-} 5,246,925	09-21-1993	DeLuca et al	
		^{US-} 5,237,110	08-17-1993	DeLuca et al	
		^{US-} 5,086,191	02-04-1992	DeLuca et al	
		^{US-} 4,666,634	05-19-1987	Miyamoto et al	
		US-			
		US-			
		US-			· ·
		US-			

	FOREIGN PATENT DOCUMENTS								
Examiner Cite Initials* No.		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages				
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T6			
		0184206	12-04-1985	Europe					
		0078704	04-29-1987	Europe					
		0387077	09-03-1990	Europe					
		0474517	11-03-1992	Europe					
		0480572	04-15-1992	Europe					
		0516410	12-02-1992	Europe					

Examiner	Date	
Signature	Considered	
_		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. The Interest of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known

Substitute for form 1449/PTO Application Number Filing Date February 17, 2004 INFORMATION DISCLOSURE First Named Inventor Hector F. DeLuca STATEMENT BY APPLICANT Art Unit 1616 (Use as many sheets as necessary) **Examiner Name** Qazi, Sabiha Naim

1256-00947 Attorney Docket Number Sheet

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant		
	ļ	Number-Kind Code ^{2 (F known)}			Figures Appear		
	1	US-					
		US-					
		US-					
	<u> </u>	US-					
_	1	US-					
	 	US-					
		US-					
		US-					
		US-					
	<u> </u>	US-					
		US-					
		US-					
	-	US-					
		US-					
	1	US-					
	<u> </u>	US-					
	l	US-	+				
	-	US-					
		US-					

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		WO90/09991	09-07-1990	Calverley et al		
		WO96/01811	01-25-1996	Posner		
	-					<u> </u>

Examiner	Date	
Signature	Considered	
	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		•	e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number		
			CLOSURE	Filing Date	February 17, 2004	
STATEMENT BY APPLICANT				First Named Inventor	Hector F. DeLuca	
	(Use as many she	ets as n	ecessary)	Art Unit	1616	
		-		Examiner Name	Qazi, Sabiha Naim	
Sheet	3	of	4	Attorney Docket Number	1256-00947	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Baggiolini et al, "Stereochemical Total Synthesis of 1a,25-Dihydroxycholecalciferol and 1Beta,25-Dihydroxyerocalciferol", Journal of Organic Chemistry, 51, pp. 3098-3108, 1986.	
		Bouillon et al, "Biological Activity of Dihydroxylated 19-Nor-(Pre)Vitamin D3", Bioactivity of 19-Nor-Pre D, Vol. 8, No. 8, pp. 1009-1015, 1993.	
		Chemical Abstracts, "Chemistry of Synthetic High Polymers", Vol. 110, No. 10, Abstract 110: 82505v, March 6, 1989.	
		Chemical Abstracts, XP-002066055, Vol. 121, No. 21, November 21, 1994.	
		Fujishima et al, "Synthesis and Biological Activity of 2-Methyl-20-EPI Analogues of 1Alpha,25-Dihydroxyvitamin D3," Bioorganic & Medicinal Chemistry Letters, 8, pp. 2145-2148, 1998.	
		Kiegiel et al, "Chemical Conversion of Vitamin D3 to its 1,25-Dihydroxy Metabolite", Tetrahedron Letters, Vol. 31, No. 43, pp. 6057-60660, 1991.	
		Konno et al, "A Novel and Practical Route to A-Ring Enyne Synthon for 1Alpha,25-Dihydroxyvitamin D3 Analogs: Synthesis of A-ring Diastereomers of 1Alpha,25-Dihydroxy-Vitamin D3 and 2-Methyl-1,25-Dihydroxyvitamin D3," Bioorganic & Medicinal Chemistry Letters, 8, pp. 151-156, 1998.	
		Okano et al, "Regulatory Activities of 2b-(3-Hydroxypropoxy)-1a,25-Dihydroxyvitamin D3. A Novel Synthetic Vitamin D3 Derivative on Calcium Metabolism", Biochemical and Biophysical Research Communications, Vol. 163, No. 3, pp. 1444-1449, September 29, 1989.	
	_	Perlman et al, "1a,25-Dihydroxy-19-Nor-Vitamin D3. A Novel Vitamin D-Related Compound with Potential Therapeutic Activity", Tetrahedron Letters, Vol. 31, No. 13, pp. 1823-1824, February 1990.	
		Posner et al, "2-Fluoroalkyl A-Ring Analogs of 1,25-Dihydroxyvitamin D3-Stereocontrolled Total Synthesis via Intramolecular and Intermolecular Diels-Alder Cycloadditions. Preliminary Biological Testing", Journal of Organic Chemistry, 60, pp. 4617-4628, 1995.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent And Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent AND TRADEMARK OF COME

	e for form 1449/PTO			e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
1				Application Number		
			CLOSURE	Filing Date	February 17, 2004	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Hector F. DeLuca	
	(Use as many sh	eets as ni	ecessary)	Art Unit	1616	
	(OSC as many sin			Examiner Name	Qazi, Sabiha Naim	
Sheet	4	of	4	Attorney Docket Number	1256-00947	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*			T²
		Posner et al, "Stereocontrolled Synthesis of a Trihydroxylated A Ring as an Immediate Precursor to 1Alpha,2Alpha,25-Trihydroxyvitamin D3", Journal of Organic Chemistry, 56, pp. 4339-4341, April 15, 1995.	
		Sarandeses et al, "Synthesis of 1Alpha,25-Dihydroxy-19-Norprevitamin D3", tetrahedron Letters, pp. 5445-5448, April 1992.	
		Sicinski et al, "New 1Alpha,25-Dihydroxy-19-Norvitamin D3 Compounds of High Biological Activity: Synthesis and Biological Evaluation of 2-Hydroxymethyl, 2-Methyl, and 2-Methylene Analogues," Journal of Medical Chemistry, 41, pp. 4662-4674, 1998.	
		Slatopolsky et al, "A New Analog of Calcitriol, 19-Nor-1,25-(OH)2 D2 Suppresses Parathyroid Hormone Secretion in Uremic Rats in the Absence of Hypercalcemia", American Journal of Kidney Disorders, 26(5), 832-60, 1995.	
-		Suhara et al, "Synthesis and Biological Evaluation of Novel 2Alpha-Substituted 1Alpha,25-Dihydroxyvitamin D3 Analogues," Biological & Medicinal Chemistry Letters, 10, pp. 1129-1132, March 16, 2000.	
	-		

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: